Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
Altimmune management will host a conference call at
Conference Call Information: |
|
Date: Time: International Dial-in: Conference ID: Webcast: |
(844) 615-6509 (918) 922-3148 4557398 https://edge.media-server.com/mmc/p/5www3cgz |
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor and Media Contact:
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com
Source: Altimmune, Inc